戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                             We categorised 93 features robust and 6 limited robustness (s
2                                                             We categorised all uncommon mutations as: point mutations or
3                                                             We categorised complications as severe or non-severe.
4                                                             We categorised counties into quintiles on the basis of the pe
5                                                             We categorised countries by LINAC shortage grade: grade 0 (LS
6                                                             We categorised countries into five epidemic patterns: norther
7                                                             We categorised deaths based on VDC weapon type.
8                                                             We categorised follow-up time in mutually exclusive episodes
9                                                             We categorised interventions as those seeking to increase dem
10                                                             We categorised participants as HIV negative, known HIV infect
11 the cutoff point of 4 (indicating high risk of depression), we categorised participants who changed from below the cutoff
12                                                             We categorised patients into two strata on the basis of CNS s
13                                                             We categorised studies and funding by disease, cross-cutting
14                                                             We categorised studies on the basis of the JPIAMR strategic r
15                                                             We categorised the 31 provinces into four regions according t
16                                                    Finally, we categorised the localisation of the membranous/cortical pr
17 e effectiveness against single antigens (G-type or P-type), we categorised them as either single-antigen vaccine type or
18                                                             We categorised them into 3 levels with entry into the health
19                                                             We categorised visits into a binary variable of any HIV risk